Dexlansoprazole

證據等級: L5

預測適應症: 10 個

Dexlansoprazole: From Erosive Esophagitis to Active Peptic Ulcer Disease

One-Sentence Summary

Dexlansoprazole is a dual delayed-release proton pump inhibitor (PPI), originally approved for healing erosive esophagitis and managing gastroesophageal reflux disease (GERD). The TxGNN model predicts it may be effective for Active Peptic Ulcer Disease, with 20 clinical trials and 4 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Erosive esophagitis / Gastroesophageal reflux disease (GERD)
Predicted New Indication	Active Peptic Ulcer Disease
TxGNN Prediction Score	99.999%
Evidence Level	L1
Saudi Arabia Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current evidence pack. Based on well-established pharmacological knowledge, dexlansoprazole irreversibly inhibits the H⁺/K⁺-ATPase proton pump in gastric parietal cells, dramatically raising intragastric pH to create the acid-suppressed environment necessary for mucosal healing. Its distinguishing feature is a dual delayed-release (DDR) formulation that produces two plasma concentration peaks (Tmax at ~1–2 h and ~4–5 h), extending acid suppression beyond what conventional once-daily PPIs can achieve.

Both erosive esophagitis and peptic ulcer disease share the same root pathophysiology: gastric acid eroding a mucosal surface that has lost its protective barriers — whether through NSAID use, H. pylori infection, or other insults. This mechanistic overlap means that sustained, high-level acid suppression directly addresses peptic ulcer healing in the same way it heals esophageal erosions. Two pivotal Phase 3 registration trials of dexlansoprazole itself (NCT00251693 and NCT00251719, enrolling over 2,000 patients each) have already demonstrated its efficacy in acid-related mucosal healing, establishing the pharmacological foundation.

Furthermore, dexlansoprazole's parent compound lansoprazole (AG-1749) holds established global approvals for both gastric and duodenal ulcer treatment and is widely used as an active comparator in peptic ulcer trials worldwide. The TxGNN model's high-confidence prediction (rank #42 globally) therefore reflects a pharmacologically coherent and clinically well-supported extrapolation rather than a speculative leap.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00251693	Phase 3	Completed	2,038	Dexlansoprazole (TAK-390MR) 60 mg/90 mg vs lansoprazole 30 mg — 8-week healing of endoscopically confirmed erosive esophagitis; pivotal registration trial directly establishing dexlansoprazole efficacy in acid-related mucosal healing
NCT00251719	Phase 3	Completed	2,054	Parallel pivotal study: dexlansoprazole MR 60 mg and 90 mg vs lansoprazole 30 mg for erosive esophagitis healing; together with NCT00251693 constitutes the core registration evidence package
NCT05010954	Phase 3	Completed	400	LXI-15028 50 mg vs lansoprazole 30 mg in Chinese patients with duodenal ulcer over 6 weeks; active comparator (lansoprazole class) efficacy directly demonstrated in peptic ulcer
NCT05813561	Phase 3	Completed	332	DWP14012 (P-CAB) 40 mg vs esomeprazole — modern head-to-head PPI/P-CAB comparison for acid-related mucosal disease; benchmark for class-level effectiveness
NCT04784910	Phase 3	Completed	423	DWP14012 20 mg vs lansoprazole 15 mg for NSAID-induced peptic ulcer prevention; non-inferiority of newer acid blocker to lansoprazole confirmed
NCT04840550	Phase 3	Unknown	390	Tegoprazan 25 mg vs lansoprazole 15 mg for prevention of gastroduodenal ulcers in long-term NSAID users; lansoprazole serves as benchmark active comparator
NCT01506986	Phase 4	Completed	30,024	HEAT trial — H. pylori eradication vs placebo in aspirin users; large-scale landmark trial validating the PPI-based strategy in ulcer prevention and demonstrating role of acid suppression class
NCT03675672	Phase 4	Recruiting	154	Misoprostol + lansoprazole vs lansoprazole alone for prevention of recurrent idiopathic gastroduodenal ulcer bleeding; evaluates long-term PPI maintenance in active ulcer management
NCT07533266	Phase 4	Not Yet Recruiting	360	Fexuprazan 20 mg vs lansoprazole 15 mg for NSAID-induced peptic ulcer prevention; upcoming trial reaffirming lansoprazole class as the reference standard
NCT07479056	N/A	Recruiting	400	Fexuprazan vs lansoprazole 30 mg for upper GI bleeding prevention in high-risk patients on dual antiplatelet therapy post-PCI; indirect comparative data relevant to PPI gastric protection

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38345252	2024	Systematic Review / Network Meta-analysis	The American Journal of Gastroenterology	Compares P-CAB vs all PPI agents for healing severe (Grade C/D) esophagitis; provides the highest level of comparative evidence for PPI class effectiveness across acid-related mucosal diseases
41809210	2026	Expert Consensus	World Journal of Gastrointestinal Pharmacology and Therapeutics	Indian multidisciplinary expert consensus on comprehensive management of acid peptic disorders (GERD, peptic ulcer disease, functional dyspepsia); addresses overlapping pathophysiology and appropriate acid suppressant use including risks of unsupervised PPI consumption
18821474	2008	Drug Review	Current Opinion in Investigational Drugs	Early clinical overview of dexlansoprazole as a modified-release enantiomer of lansoprazole; summarizes NDA filing for gastric acid-related diseases and Phase 2 GERD data, establishing the regulatory scope of the drug's intended indications
36150104	2022	Basic Science / Mechanistic Study	Journal of the Chinese Medical Association	Investigates PPI-mediated vacuolar-type ATPase suppression and ER stress induction, explicitly naming dexlansoprazole; provides mechanistic context for understanding PPI pharmacological effects beyond proton pump inhibition

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Dexlansoprazole's dual delayed-release design provides mechanistically superior and sustained acid suppression that is directly relevant to peptic ulcer healing. Two large-scale Phase 3 registration trials of dexlansoprazole itself (>4,000 patients combined) and numerous completed Phase 3 trials of the PPI class in peptic ulcer disease collectively support Level L1 evidence. The prediction represents a pharmacologically coherent extension of an established drug class into a closely related acid-related indication, with minimal mechanistic uncertainty.

To proceed, the following is needed:

Saudi Arabia registration pathway: Dexlansoprazole is not currently approved or marketed in Saudi Arabia (SFDA); a registration dossier or import approval application must be initiated
Complete safety documentation: Full package insert warnings, contraindications, and drug-drug interaction data are required before clinical use — particularly the clopidogrel interaction (addressed in NCT00942175 Phase 1 data but not yet structured in this evidence pack)
Regulatory strategy clarification: Determine whether peptic ulcer constitutes a new indication requiring a separate clinical trial or whether PPI class evidence plus dexlansoprazole PK/PD data suffice for a label extension
MOA documentation: Obtain formal DrugBank or prescribing information MOA data to complete the evidence pack (currently flagged as DG002 — High severity data gap)
Local pharmacoeconomic analysis: Compare dexlansoprazole against already-available PPIs and emerging P-CABs in the Saudi market to support formulary positioning
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.